These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24155892)

  • 1. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
    Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
    PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
    Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
    Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
    Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
    Mimeault M; Johansson SL; Henichart JP; Depreux P; Batra SK
    Mol Cancer Ther; 2010 Mar; 9(3):617-30. PubMed ID: 20179163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
    Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
    J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
    Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
    Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
    Corkery B; Crown J; Clynes M; O'Donovan N
    Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
    Zhang W; Zhang W; Wang L; Zheng J; Xiao F
    Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):385-90. PubMed ID: 21569641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M; Yuan Y; Pan YY; Zhang Y
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
    Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B
    Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
    Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC
    Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
    Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
    Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.